Centre has rolled out an allocation plan for distribution of anti-viral drug Remdesivir in 19 states reporting higher number of COVID-19 cases.
The allocation includes bulk purchases made by the States as well as supplies through private distribution channels.
This initial allocation is till 30th of this month and it will be reviewed constantly in consultation with the States to ensure all needs can be met within the available supplies.
The Health Ministry has asked the manufacturers to consider supply orders already made to them, geographical proximity with a State and terms of supply and give inputs for mapping of manufacturers to states for the allocated volumes.
They have also been directed to manufacture and dispatch the supplies as per the agreed State allocation and mapping.
All States may place their supply orders to manufacturers either by the Government purchase or distribution channel as per the allocation and manufacturer-wise mapping.
The States have been asked to immediately appoint State Nodal officers who will be responsible for unrestricted and timely movement of Remdesivir within their States.
Control Room set up by National Pharmaceutical Pricing Authority will be responsible for monitoring the operations as per the allocations to states.
A Whatsapp group comprising Nodal officers of States is being created to coordinate unhindered movement of Remdesivir within the country.
Keeping in mind the sudden surge in demand for Remdesivir Injection, the government has ramped up the manufacturing capacity of its domestic manufacturers.
The government has extended all support to manufacturers.
The production capacity is being ramped up from current level of 38 lakh vials per month to 74 lakh vials per month, and 20 additional manufacturing sites have been approved.
Export of Remdesivir has also been prohibited to shore up domestic supplies.